NorthWest Biotherapeutics Inc (NWBO)

[ou71764]

Flipper,

This is one part that you highlighted:

"All patients that generated a systemic CTL response showed no MRI evidence of progressive disease at the time of vaccination [initiation]. Conversely, no patient with actively progressive disease developed statistically significant 'cytotoxicity. (which means being toxic to cancer cells)." This is really really important.

I get the first part: the vaccine is more effective if the cancer is stable at the time the vaccine is administered.

But then it says that if a patient has progressive disease, that there is no cytotoxicity. And cytotoxicity means being toxic to cancer cells. So cytotoxicity is good, in that it's bad for cancer cells.

If that's the case then I guess I'm glad the trial excludes the patients with progressive disease. But I'd rather that the vaccine could at least "slow down" progressive cancer.